Client News

OKYO Pharma Limited: U.S. Patent issued for use of OK-101 to treat DED
Home / Client News / OKYO Pharma Limited: U.S. Patent issued for use of OK-101 to treat DED

London and Boston, MA, December 14, 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced that the patent entitled “Methods of Lowering Blink Reflex for the Treatment of Dry Eye Disease” has been issued by the United States Patent and Trademark Office (“USPTO”) as U.S. Patent No. 11,197,906. This patent contains key claims covering OK-101 to treat dry eye disease. OK-101 is OKYO’s lead pre-clinical compound and is a novel long-acting GPCR-based anti-inflammatory drug candidate. The work recited in this patent lays out the potential of OK-101, a lipidated chemerin analogue, to treat patients with dry eye disease (“DED”). The drug, planned to be administered topically, is anticipated to open human studies with a Phase 2 clinical trial in DED patients in Q4, 2022.



If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.


Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This